VolitionRX Limited (ARCA:VNRX) insider have most recently took part in a trading activity. On Sep 19, 2017 Vanston David Cecil, CHIEF FINANCIAL OFFICER bought 2,750 shares having total worth of $7,810 at the price of $2.84 per share, following the transaction a total of 2,750 shares owned by Vanston David Cecil.
The stock has experienced a total of 2 insider trades in the past three months. These trades include 2 buy trades. Furthermore, over the past 12 months , the stock was traded 3 times by insiders. an employee of the company was the buyer in 3 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of VolitionRX Limited (ARCA:VNRX) traded down 0.74% on Sep 18, 2017, hitting $2.68. 18,936 shares of the company’s stock traded hands. VolitionRX Limited has a 52 week low of $2.45 and a 52 week high of $5.64. The company’s market cap is $133 million.
VolitionRX Limited (ARCA:VNRX) last announced its earnings results on Aug 9, 2017. The company reported -0.13 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.14 by $0.01. During the same quarter in the previous year, the company posted -0.13 earnings per share.
|earnings per share||-0.13||-0.13||-0.12||-0.15||-0.13||-0.13||-0.15||-0.16||-0.10||-5.41|
VolitionRX Ltd was incorporated on September 24, 1998 in the State of Delaware under the name “Standard Capital Corporation”. On September 22, 2011, the Company was revived under the new name of VolitionRX Limited. The name change to VolitionRX Limited was approved by FINRA on October 7, 2011 and became effective on October 11, 2011. It is development stage life science company address the need for accurate, fast, inexpensive and scalable tests for detecting and diagnosing cancer and other diseases. The Company is a development stage which operates in the process of discovering and developing blood-based diagnostic tests intended for future commercialization through various channels. The Company has developed fifteen blood test assays. Each assay that the Company has developed can be commercialized for two distinct markets, the clinical in-vitro diagnostics market and the research use only market. Commercializing products on the research use only market means that the Company intends to sell its products to medical schools, universities and commercial research and development departments for research use only. Products placed on the research use only market may be used for any research purpose, even if the products are being studied or tested for uses other than those intended. Research use only market products are not to be used for patient diagnosis. Commercializing products on the clinical in-vitro diagnostics market means that the Company intends to sell its future products to be used in hospitals, clinics and others for patient diagnosis. None of the assays that the Company has currently developed are available for sale on the clinical in-vitro diagnostics market. The Company’s diagnostic products are designated as “medical devices” by the FDA. It faces competition primarily from large healthcare, pharmaceutical and diagnostic companies such as Abbott Laboratories Inc., Philips, Cepheid Inc., GE Healthcare, Siemens, Gen-Probe Incorporated, EpiGenomics AG, MDxHealth SA, Roche Diagnostics and Sequenom, Inc.
Latest posts by William White (see all)
- Insider Trading Activity in: Second Sight Medical Products, Inc. $EYES - July 19, 2018
- Insider Trading Activity in: Internationa Flavors & Fragrances, Inc. $IFF - July 19, 2018
- Insider Trading Update: Opko Health, Inc. $OPK - July 19, 2018